The RAS targeting therapies market is anticipated to grow at an annualized rate of over 50%, till 20

Given that conventional therapies have been unable to exhibit significant efficacy in the treatment of RAS mutated cancers, novel drugs, specifically targeting the RAS gene, have emerged as a promising alternative, supported by extensive research

Roots Analysis has announced the addition of “RAS Targeting Therapies Market, 2021-2031” report to its list of offerings.

Growing research activity in the RAS targeting domain has resulted in a surge in the interest of biopharmaceutical developers in this rapidly evolving sector. These therapies are being developed against specific oncogenic RAS mutations that are believed to be responsible for close to 30% of the overall human cancers. Moreover, the first and only approved RAS targeted therapy, named LUMAKRASTM, has provided a boost to this market, by providing a treatment for a previously deemed undruggable target.

To order this 140+ page report, which features 95+ figures, please visit

Leave a Reply

Your email address will not be published. Required fields are marked *